Regulatory Considerations in Application of Encapsulated Cell Therapies

  • J. van Zanten
  • Paul de Vos
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 670)


The encapsulation of tissue in semi-permeable membranes is a technology with high potential and in due time several new therapies based on this technology will be tested in clinical trials. Recent, new legislation requires that these investigational medicinal products used in clinical trials Phase I must be produced according to Good Manufacturing Practice (GMP). Consequently, the activities of GMP are expanding to the field of research and researchers might need to change developed protocols in order to meet GMP legislation. This chapters gives an overview of the overall guidelines covering GMP and more specific guidelines dealing with cell based therapies and gene therapy.


Medicinal Product Good Manufacture Practice Investigational Medicinal Product Advance Medicinal Therapy Product Regulatory Consideration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Visted T, Bjerkvig R, Enger PO. Cell encapsulated technology as a therapeutic strategy for CNS malignancies. Neuro-oncology 2001; 3:201–210.PubMedGoogle Scholar
  2. 2.
    Cirone P, Potter M, Hirte H et al. Immunoisolation in cancer gene therapy. Current Gene Therapy 2006; 6:181–191.CrossRefPubMedGoogle Scholar
  3. 3.
    De Vos P, Faas MM, Strand B et al. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 2006; 27:5603–5617.CrossRefPubMedGoogle Scholar
  4. 4.
    Caliafore R, Basta G, Luca G et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 2006; 29:137–138.CrossRefGoogle Scholar
  5. 5.
    Immel BK. A brief history of the GMP’s: the power of storytelling. BioPharm International 2000; 61:26–36.Google Scholar
  6. 7.
    Möritz A. The new GMP environment for investigational medicinal products in the european union. BioProcess Int 2005; 3:28–38.Google Scholar
  7. 8.
    Rosin LJ. Regulatory affairs; If you didn’t write it down, it didn’t happen. 2006. BioProcess Int Supplement 2006; 4(3):16–23.Google Scholar
  8. 10.
    Mingam I, Dupraz-Poiseau A. Current and future frameworks for cell-and tissue-based products. Bio-Process International 2006; 4(5):12–17.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • J. van Zanten
    • 1
  • Paul de Vos
    • 1
  1. 1.Department of PLG/Medical Biology, University Medical Center GroningenUniversity of GroningenGroningenthe Netherlands

Personalised recommendations